|
End-of-day quote
Shenzhen S.E.
25/08/2026
|
5-day change | 1st Jan Change | ||
| 11.77 CNY | +2.97% |
|
-1.51% | -8.48% |
Company Valuation: Yixintang Pharmaceutical Group Co., Ltd.
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 22,959 | 18,782 | 13,803 | 7,625 | 7,383 | 6,757 | - | - |
| Change | - | -18.19% | -26.51% | -44.76% | -3.16% | -8.48% | - | - |
| Enterprise Value (EV) 1 | 21,903 | 16,608 | 11,574 | 5,707 | 6,451 | 5,418 | 5,127 | 4,629 |
| Change | - | -24.17% | -30.31% | -50.69% | 13.04% | -16.02% | -5.36% | -9.72% |
| P/E | 24.7x | 18.6x | 25.2x | 67.6x | 28.1x | 12.6x | 10.6x | 8.92x |
| PBR | 3.49x | 2.53x | 1.78x | 1.02x | 1.03x | 0.9x | 0.86x | 0.82x |
| PEG | - | 2.14x | -0.6x | -0.9x | 0x | 0x | 0.6x | 0.5x |
| Capitalization / Revenue | 1.57x | 1.08x | 0.79x | 0.42x | 0.43x | 0.37x | 0.35x | 0.33x |
| EV / Revenue | 1.5x | 0.95x | 0.67x | 0.32x | 0.37x | 0.3x | 0.27x | 0.23x |
| EV / EBITDA | 16.9x | 11x | 10.6x | 3.13x | 9x | 2.93x | 2.45x | 1.95x |
| EV / EBIT | 20.5x | 13.4x | 11.8x | 20.5x | 15.3x | 6.03x | 4.9x | 3.79x |
| EV / FCF | - | - | 6.14x | 3.89x | 4.76x | 3.72x | 2.62x | 1.95x |
| FCF Yield | - | - | 16.3% | 25.7% | 21% | 26.9% | 38.1% | 51.3% |
| Dividend per Share 2 | 0.3 | 0.4 | 0.4 | 0.3 | 0.2 | 0.474 | 0.5339 | 0.6487 |
| Rate of return | 0.78% | 1.27% | 1.73% | 2.3% | 1.56% | 4.03% | 4.54% | 5.51% |
| EPS 2 | 1.561 | 1.697 | 0.9206 | 0.1927 | 0.4571 | 0.934 | 1.112 | 1.32 |
| Distribution rate | 19.2% | 23.6% | 43.4% | 156% | 43.8% | 50.8% | 48% | 49.1% |
| Net sales 1 | 14,585 | 17,432 | 17,380 | 18,000 | 17,336 | 18,047 | 19,158 | 20,564 |
| EBITDA 1 | 1,295 | 1,511 | 1,087 | 1,823 | 716.6 | 1,851 | 2,090 | 2,373 |
| EBIT 1 | 1,066 | 1,243 | 982.9 | 278 | 422.4 | 897.9 | 1,046 | 1,223 |
| Net income 1 | 921.5 | 1,010 | 549.4 | 114.1 | 263.4 | 545.1 | 649.7 | 779 |
| Net Debt 1 | -1,056 | -2,174 | -2,229 | -1,917 | -932 | -1,340 | -1,630 | -2,128 |
| Reference price 2 | 38.51 | 31.51 | 23.16 | 13.02 | 12.86 | 11.77 | 11.77 | 11.77 |
| Nbr of stocks (in thousands) | 596,181 | 596,071 | 596,005 | 585,604 | 574,128 | 574,128 | - | - |
| Announcement Date | 14/03/22 | 17/03/23 | 19/03/24 | 27/04/25 | 28/04/26 | - | - | - |
1CNY in Million2CNY
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
| 12.24x | 0.29x | 2.82x | 4.15% | 976M | ||
| 17.06x | 0.7x | 10.4x | -.--% | 15.19B | ||
| 20.94x | 0.8x | 13.44x | 1.07% | 6.48B | ||
| 16.71x | 0.75x | 7.83x | 2.23% | 6.38B | ||
| 14.77x | 0.97x | 6.97x | 2.85% | 4.26B | ||
| 14.58x | 1.25x | 7.65x | 5.51% | 3.25B | ||
| 13.32x | 0.54x | 4.32x | 5.19% | 2.94B | ||
| 13.83x | 0.83x | 6.24x | 4.64% | 2.93B | ||
| 30.71x | - | - | - | 2.39B | ||
| Average | 17.13x | 0.77x | 7.46x | 3.2% | 4.98B | |
| Weighted average by Cap. | 17.34x | 0.78x | 9.04x | 1.98% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- 002727 Stock
- Valuation Yixintang Pharmaceutical Group Co., Ltd.
Select your edition
All financial news and data tailored to specific country editions
















